Opsumit vs Tyvaso
Side-by-side cost comparison based on Medicare Part D data
Opsumit
Macitentan
Manufactured by Janssen
Tyvaso
Treprostinil (inhaled)
Manufactured by United Therapeutics
Opsumit costs 29% less per claim than Tyvaso ($10,186.00 vs $14,349.00). A generic version of Opsumit is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Opsumit | Tyvaso |
|---|---|---|
| Avg Cost Per Claim | $10,186.00 | $14,349.00 |
| Total Medicare Spending | $876.0M | $1.2B |
| Total Beneficiaries | 8,400 | 8,400 |
| Total Claims | 86,000 | 86,000 |
| Annual Cost/Patient | $104,286.00 | $146,905.00 |
| Year-over-Year Change | +4.6% | +24.6% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Janssen | United Therapeutics |
| Condition | Pulmonary Hypertension | Pulmonary Hypertension |
| Generic Name | Macitentan | Treprostinil (inhaled) |
Opsumit vs Tyvaso: What the Data Shows
Opsumit (Macitentan) and Tyvaso (Treprostinil (inhaled)) are both used to treat pulmonary hypertension. Based on Medicare Part D data, Opsumit costs $10,186.00 per claim, which is 29% less than Tyvaso at $14,349.00 per claim.
Medicare spent $876.0M on Opsumit and $1.2B on Tyvaso. In terms of patient reach, Tyvaso serves more beneficiaries (8,400 vs 8,400).
Year-over-year spending changed +4.6% for Opsumit and +24.6% for Tyvaso. Tyvaso saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Opsumit is cheaper at $10,186.00 per claim, compared to $14,349.00 for Tyvaso. That makes Opsumit about 29% less expensive per claim based on Medicare Part D data.
Yes, both Opsumit and Tyvaso are used to treat pulmonary hypertension. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Macitentan and generic Treprostinil (inhaled) can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $876.0M on Opsumit covering 8,400 beneficiaries, and $1.2B on Tyvaso covering 8,400 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.